MAZE
Maze Therapeutics, Inc.
26.40$
+0.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -98.5% | -100.0% | – | – | – | – | – | -100.0% | – | |
| – | -2.8% | -2.7% | – | – | -10.5% | -3.0% | -5.1% | – | – | -11.0% | – | – | |
| – | – | – | – | -98.5% | -128.2% | – | – | – | – | – | – | – | |
| – | -17.5% | +36.3% | -10.7% | +1.6% | +11.9% | +24.1% | +1.9% | -10.4% | +9.4% | +22.2% | +3.7% | – | |
| – | +21.4% | -12.4% | -3.9% | +16.5% | +9.3% | +4.1% | +7.0% | -7.1% | +34.9% | +18.3% | +5.6% | – | |
| – | -8.6% | +21.5% | -9.2% | +5.0% | +11.2% | +19.1% | +1.2% | -8.0% | +13.9% | +22.8% | +4.2% | – | |
| – | – | – | – | -117.4% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | +7.5% | – | |
| – | – | – | – | -117.8% | – | – | – | – | – | – | – | – | |
| – | – | – | – | -116.2% | – | – | – | – | – | – | – | – | |
| – | – | – | – | -117.8% | – | – | – | – | – | – | – | – | |
| – | – | – | – | -117.1% | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.